Edwards Lifesciences revenue
Edwards Lifesciences's revenue was $6.07bn in fiscal 2025, up 11.5% on the year before. Since fiscal 2009 ($1.32bn) it has grown at a compound 10.0% a year. Over the last twelve months it was $6.51bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,321 | 1,447 | 1,679 | 1,900 | 2,046 | 2,323 | 2,494 | 2,964 | 3,435 | 3,723 | 4,348 | 4,386 | 5,233 | 4,464 | 5,010 | 5,440 | 6,068 | 6,512 |
| Growth on the year before | — | +9.5% | +16.0% | +13.2% | +7.7% | +13.6% | +7.4% | +18.8% | +15.9% | +8.4% | +16.8% | +0.9% | +19.3% | −14.7% | +12.2% | +8.6% | +11.5% | — |
| Gross profit | 922 | 1,039 | 1,189 | 1,409 | 1,529 | 1,697 | 1,877 | 2,166 | 2,560 | 2,783 | 3,234 | 3,306 | 3,984 | 3,740 | 4,032 | 4,322 | 4,733 | 5,069 |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $4.5B | 74.0% | ▲ 9.3% |
| Surgical Heart Valve Therapy | $1B | 17.0% | ▲ 4.9% |
| Transcatheter Mitral and Tricuspid Therapies | $551M | 9.1% | ▲ 56.4% |
From Edwards Lifesciences's 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Edwards Lifesciences | $6.51bn | 14.6% | 15.3% |
| Steris | $6.04bn | 8.4% | 9.0% |
| ResMed| | $5.73bn | 9.0% | 9.4% |
| Bausch & Lomb Corp | $5.42bn | 8.9% | 10.9% |
| Dexcom | $5.10bn | 13.0% | 14.5% |
| Zimmer Biomet | $8.51bn | 8.6% | 5.7% |
Compare with peers
Head to head: EW vs STEEW vs RMDBLCO vs EWEW vs ZBH
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies